Hepatology International

Article	Citations
The safety profile of endoscopic variceal ligation in patients with esophageal varices	132
HBV in pregnancy: time to consider tenofovir alafenamide (TAF)	94
Metabolically healthy obese and MAFLD: does weight status alone matter?	73
Platelets in acute liver failure: an innocent bystander or instigator?	72
Defining the evaluation standards for the cholangiocytic component in cHCC-CCA: a pathology-based perspective	71
Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk	62
N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD	59
Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression	56
Diagnosis of significant liver fibrosis in patients with chronic hepatitis B using a deep learning-based data integration network	51
Commentary on “Comparison of relaxed verses standard cut-offs of rotational thromboelastometry for guiding blood product use before invasive procedures in advanced cirrhosis: a randomized controlled t	49
Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial	49
Methodological reflections on vasoconstrictor use in refractory ascites: bridging trial rigor and real-world relevance	47
Response to: “Is laparoscopic hepatectomy superior to laparotomic hepatectomy? The debate continues”	46
Predictive value of soluble PD-1 for HBsAg loss in HbeAg-negative patients with chronic hepatitis B: results from a prospective study	44
p53 regulates glucose metabolic reprogramming in MASLD-related hepatocellular carcinoma via modulating mitochondrial pyruvate carriers	43
Antibiotic prophylaxis in upper gastrointestinal bleeding with Child-Pugh A cirrhosis: need for objective infection markers and broader studies	42
Antioxidant, selenium and risk of nonalcoholic fatty liver disease, more than causality	42
Small extracellular vesicles derived from lipotoxic hepatocytes transport FASN to promote hepatic stellate cell activation	42
Can living donor liver transplantation provide similar outcomes to deceased-donor liver transplantation for hepatocellular carcinoma? A systematic review and meta-analysis	41
Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis	39
Pure laparoscopic versus open left lateral hepatectomy in pediatric living donor liver transplantation: a review and meta-analysis	38
Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study	38
Comment on “Comparison of diagnostic criteria for fatty liver disease in assessing cardiac dysfunction: a cross-sectional study”	37
Good outcomes of living donor liver transplant in primary sclerosing cholangitis: an experience from North India	37
Liver stiffness can predict decompensation and need for beta-blockers in compensated cirrhosis: a step beyond Baveno-VI criteria	37

Impact of CT-relevant skeletal muscle parameters on post-liver transplantation survival in patients with hepatocellular carcinoma	37
Comment on “Diabetes mellitus is linked to higher mortality in alcohol‑related acute‑on‑chronic liver failure”	35
Exosome GLUT1 derived from hepatocyte identifies the risk of non-alcoholic steatohepatitis and fibrosis	35
Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets	35
The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes	35
Development of nomograms to predict outcomes for large hepatocellular carcinoma after liver resection	34
The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease	33
Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy	33
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis	33
Reply to: “developing real‑world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond”	32
Methodological considerations in linking depression to metabolic dysfunction-associated steatotic liver disease: insights for future study design	32
Letter to the editor: Treating portal vein thrombosis in cirrhosis: is anticoagulation therapy overestimated?	32
Targeting immuno-metabolism and anti-viral immune responses in chronic hepatitis B	32
Metabolic dysfunction-associated steatotic liver disease increases the incidence of metachronous liver metastases from TNM stage 0–II colorectal cancer	31
Novel and simplified model for the precise identification of concurrent bacterial infections in patients aged 60 years and older with acute-on-chronic liver diseases: a nationwide, multicentre, prospe	31
Correction to: Targeting ferroptosis in hepatocellular carcinoma	30
Prospects for treatment of esophageal varices considering the safety of endoscopic band ligation	30
The dynamic patterns of metabolic-associated fatty liver disease and its severity and risk of cardiovascular disease	29
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients	29
Image-matching digital macro-slide—a novel pathological examination method for microvascular invasion detection in hepatocellular carcinoma	28
The relationship between CXCR6+CD8+T cells and clinicopathological parameters in patients with primary biliary cholangitis	28
Identifying the early predictors of non-response to steroids in patients with flare of autoimmune hepatitis causing acute-on-chronic liver failure	28
Role of splenic hepatic elastography ratio in differentiating non-cirrhotic portal fibrosis and chronic liver disease in children and adolescents	28
Drug–drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study	28
Metabolic dysfunction associated fatty liver disease in healthy weight individuals	28
Gut microbes associated with functional cure of chronic hepatitis B	27
Comments on “Three‑year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab”	27
Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain	27
Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: a systematic review and meta-analysis	26
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan	26
Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures	26
Liver-derived extracellular vesicles from patients with hepatitis B virus-related acute-on-chronic liver failure impair hepatic regeneration by inhibiting on FGFR2 signaling via miR-218-5p	26
APASL STC 2025, Istanbul	25
Fecal microbiota transplantation in alcoholic hepatitis: new treatment paradigm or a shot in the dark?	25
Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study	25
Correction: The interplay between lymphatic system and portal hypertension: a comprehensive review	25
Correction: Liver transplantation for acute-on-chronic liver failure	25
Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis	25
Native liver survival with therapeutic plasma exchange in acutely decompensated hepatic Wilson Disease: revisiting the Dhawan index	25
Maternal and perinatal outcome in pregnancies complicated with portal hypertension: a systematic review and meta-analysis	24
Stage-specific impact of portal hypertension on outcomes after liver resection in hepatocellular carcinoma	24
MAFLD, patient-centred care, and APASL	24
The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma	24
Enhancing the understanding and management of metabolic dysfunction-associated steatotic liver disease in colorectal cancer patients: insights and future directions	24
Downregulated VISTA enhances Th17 differentiation and aggravates inflammation in patients with acute-on-chronic liver failure	24
The impact of artificial liver support system on intestinal microbiota and serum bile acid profiles in patients with acute-on-chronic liver failure: a prospective cohort study	24
Liver decompensation: the yard stick that measures indications and adverse effects of human albumin infusion	23
Recombinant human serum albumin: a true therapeutic substitute or merely a serum level elevator?	23
ChIP-seq analysis found IL21R, a target gene of GTF2I–the susceptibility gene for primary biliary cholangitis in Chinese Han	23
Distinct course of portal hypertension in patients with cirrhosis with gastric variceal bleeding as their first decompensation: a propensity score-matched study	23

Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1–AXL signal relay in liver cancer cells	23
Comment on: Low-risk individuals with primary biliary cholangitis and significant liver stiffness: prognosis and treatment	22
Benefit of adjuvant radiotherapy for gallbladder cancer: a comparability-based meta-analysis	22
The effect of transition timing of regorafenib on treatment outcomes in unresectable hepatocellular carcinoma: a real-world study	22
Comment on ‘Immunomodulation by bepirovirsen may induce killing of infected hepatocytes (B-Together study)’	21
Low skeletal muscle mass is associated with more severe histological features of non-alcoholic fatty liver disease in male	21
AARC score and urine NGAL predict terlipressin non-response and mortality in patients with acute-on-chronic liver failure	21
Diagnostic yield and novel candidate genes by next generation sequencing in 166 children with intrahepatic cholestasis	21
Enhancing the prognostic value of inflammatory markers in hepatocellular carcinoma: a thoughtful discussion	21
Sleep patterns, genetic susceptibility, and risk of cirrhosis among individuals with nonalcoholic fatty liver disease	20
Deep learning for prediction of hepatocellular carcinoma recurrence after resection or liver transplantation: a discovery and validation study	20
Gender differences in non-alcoholic fatty liver disease in obese children and adolescents: a large cross-sectional study	20
Distinctly altered lipid components in hepatocellular carcinoma relate to impaired T cell-dependent antitumor immunity	20
A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma	20
Correction to: Exosomal miR-200b-3p induce macrophage polarization by regulating transcriptional repressor ZEB1 in hepatocellular carcinoma	20
Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD	19
Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis	19
Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals	19
Skeletal muscle alterations indicate poor prognosis in cirrhotic patients: a multicenter cohort study in China	19
The association between visceral adipocyte hypertrophy and NAFLD in subjects with different degrees of adiposity	19
Stem cells therapies for liver diseases: for current practice and future goals	18
Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease	18
Drug-induced liver injury from herbal and dietary supplements: a problem in the East and West alike	18
Reduction of natural killer cells is associated with poor outcomes in patients with hepatitis B virus-related acute-on-chronic liver failure	18
Modified and alternative Baveno VI criteria based on age for ruling out high-risk varices in patients with compensated cirrhosis	18
From comorbidity to catalyst: mechanistic and therapeutic implications of diabetes mellitus in alcohol-related acute-on-chronic liver failure	17
Diet-derived antioxidants and nonalcoholic fatty liver disease: a Mendelian randomization study	17
Genetic predisposition of metabolic dysfunction-associated steatotic liver disease: a population-based genome-wide association study	17
Diversity of the nucleic acid forms of circulating HBV in chronically infected patients and its impact on viral cycle	17
Correction to: Linking the gut and liver: crosstalk between regulatory T cells and mucosa-associated invariant T cells	17
Interferon therapy improves survival in patients with hepatitis B virus-related hepatocellular carcinoma after curative surgery: a meta-analysis	17
Comment on “Cirrhotic cardiomyopathy in children with biliary atresia and genetic intrahepatic cholestasis: clinical course and outcomes”	17
The effectiveness of combination therapy with interferon and nucleoside analogs in pediatric patients with chronic hepatitis B: a systematic review and meta-analysis	17
Oxidative stress triggers hyperdynamic circulation via central neural activation in portal hypertensive rats	17
Integrated genomic analyses of hepatocellular carcinoma	17
Explainable attention-enhanced heuristic paradigm for multi-view prognostic risk score development in hepatocellular carcinoma	17
Comments on: CT-based intratumoral and peritumoral radiomics to predict the treatment response to hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 in high-risk hepatocellular carcinoma	17
Liver fat and a perturbed metabolic milieu: a consilience of factors driving liver cancer development	17
CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway	17
Metabolic dysfunction-associated fatty liver disease and heavy alcohol consumption increase mortality:A nationwide study	17
Diagnosis and management of pediatric acute liver failure: consensus recommendations of the Indian Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ISPGHAN)	16
Metabolic implications of tenofovir alafenamide in chronic hepatitis B: a commentary on cardiovascular and lipid risks	16
New progress towards elimination of mother-to-child transmission of hepatitis B virus in China	16
Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective	16
Commentary on “Predictive value of soluble PD-1 for HBsAg loss in HBeAg-negative chronic hepatitis B patients: a prospective study”	16
PIRO-CIC model can predict mortality and futility of care in critically ill cirrhosis patients in the intensive care unit	16
PIVKA-II combined with alpha-fetoprotein for the diagnostic value of hepatic tumors in children: a multicenter, prospective observational study	16
Hepatitis B virus-related intrahepatic cholangiocarcinoma originates from hepatocytes	16
Reconsiderations for the liver donation from a living donor: addressing hepatic steatosis with weight loss preconditioning	16
The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion	16
Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis	16
Gut-microbiome composition and function in progression of alcohol-associated liver disease: going beyond western experiences	15
Editorial: The safety profile of endoscopic variceal ligation in patients with esophageal varices. Authors’ reply	15
Carbohydrate-deficient transferrin is a sensitive marker of alcohol consumption in fatty liver disease	15
Nomograms should be noted	15
Low platelets: a new and simple prognostic marker for patients with hepatitis E virus-related acute liver failure	15
Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma	15
Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort	14
Global burden of cirrhosis and liver cancer due to alcohol: the past, present, and the future	14
miR-98-5p as a novel biomarker suppress liver fibrosis by targeting TGFβ receptor 1	14
Global, regional, and national burdens of cirrhosis in children and adolescents aged under 19 years from 1990 to 2019	14
Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon	14
Reply to Letter to the Editor “Hepatic irAE, ICI continuation, and survival: need for robust evidence beyond initial observations”	14
Refining meta-analyses in advanced biliary tract cancer	14
Influence of shunt occlusion on liver volume and functions in hyperammonemic cirrhosis patients having large porto-systemic shunts: a randomized control trial	14
Acute variceal bleeding portends poor outcomes in patients with acute-on-chronic liver failure: a propensity score matched study from the APASL ACLF Research Consortium (AARC)	14
Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment	14
Hepatic irAE, ICI continuation, and survival: need for robust evidence beyond initial observations	14
Predictive power of portal pressure gradient remeasured shortly after transjugular intrahepatic portosystemic shunt	14
Clinical practice guidelines on hemochromatosis: Asian Pacific Association for the Study of the Liver	14
Towards precise evaluation of steatotic liver disease subtypes and adverse pregnancy outcomes: methodological insights	14
Correction to: Complementary role of peripheral and central autonomic nervous system on insulin-like growth factor-1 activation to prevent fatty liver disease	13
Comparison of the prognostic models for mortality in idiosyncratic drug-induced liver injury	13
Exosomal miR-200b-3p induce macrophage polarization by regulating transcriptional repressor ZEB1 in hepatocellular carcinoma	13
Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma	13
Comparison of relaxed verses standard cut-offs of rotational thromboelastometry for guiding blood product use before invasive procedures in advanced cirrhosis: a randomized controlled trial	13
Correction to: Infuence of shunt occlusion on liver volume and functions in hyperammonemic cirrhosis patients having large porto-systemic shunts: a randomized control trial	13
Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease	13
Insights in a prospective investigation of cardiomyopathy in children with biliary atresia and hereditary intrahepatic cholestasis: focus on diagnosis, survival analysis, and bias control	13
Comment on “Cirrhotic cardiomyopathy in children with biliary atresia and genetic intrahepatic cholestasis: clinical course and outcomes”	13

The upregulation of Annexin A2 by TLR4 pathway facilitates lipid accumulation and liver injury via blocking AMPK/mTOR-mediated autophagy flux during the development of non-alcoholic fatty liver diseas	13
Expanding treatment indications in chronic hepatitis B: Should we treat all patients?	13
Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection	13
Reply to: The best predictive model for post-SVR HCC: can it be universal?	13
Comments on: Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis	13
How non-alcoholic fatty liver disease and cirrhosis affect the heart	13
Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period	13
Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes	13
Autophagy and extracellular vesicles in the liver endothelium: friends or foes?	13
Characteristics of microbiome-derived metabolomics according to the progression of alcoholic liver disease	13
Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA	12
BRIX1 activated by mTORC1-SP1 signaling regulates ribosome biogenesis and alternative splicing to promote hepatocellular carcinoma progression	12
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024	12
Characteristics and long-term mortality of patients with non-MAFLD hepatic steatosis	12
Safety of right liver donation after improving steatosis through weight loss in living donors: a retrospective study	12
Synthetic miR-26a mimics delivered by tumor exosomes repress hepatocellular carcinoma through downregulating lymphoid enhancer factor 1	12
Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study	12
GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial	12
Developing real-world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond	12
Presence of sarcopenia identifies a special group of lean NAFLD in middle-aged and older people	12
Response to Letter to Editor: “Systemic inflammation and prognosis in HCC: a closer look”	12
Liver fibrosis is associated with impaired bone mineralization and microstructure in obese individuals with non-alcoholic fatty liver disease	12
Impact of plasma exchange on bilirubin reduction and neurological impairment in infantile acute liver failure	11
Management of acute variceal bleeding: updated APASL guidelines	11
Complications of congenital portosystemic shunts: liver tumors are affected by shunt severity, but pulmonary and neurocognitive associations are not	11
The combination of ropeginterferon alfa-2b with anti-PD1 blockage in adjuvant therapy in HBV-related HCC	11
Functional cure is associated with younger age in children undergoing antiviral treatment for active chronic hepatitis B	11
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma	11
The causes of death in patients with nonalcoholic steatohepatitis following liver transplantation stratified using pre-liver transplant BMI	11
Risk stratification for patients with primary biliary cholangitis: early versus advanced-stage or non-cirrhosis versus cirrhosis?	11
Obesity and non-alcoholic steatohepatitis in immunotherapy for hepatocellular carcinoma	11
Key considerations in portal vein thrombosis management	11
Regarding the role of post-transplant inflammatory cytokine signature on predicting tumor recurrence after liver transplantation for hepatocellular carcinoma	11
Identification of PANoptosis-relevant subgroups and predicting signature to evaluate the prognosis and immune landscape of patients with biliary tract cancer	11
AI in fatty liver diseases: insights from recent research trends	11
Efficacy and safety of precision-guided transjugular extrahepatic portosystemic shunt (TEPS) in the management of cavernous transformation of the portal vein with portal hypertension: a case series	11
Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome	11
Impact of myosteatosis on outcomes after liver transplantation: a systematic review and meta-analysis	11
Comments on: Addition of midodrine to albumin reduces the incidence of complications of large-volume paracentesis: an RCT comparing midodrine, terlipressin, and albumins	11
Midodrine plus propranolol: potential problems and controversies behind remarkable efficacy	11
Management of spontaneous portosystemic shunts at the time of liver transplantation: treatment or observation? Results of a systematic review	11
Acute kidney injury stage 1a increases mortality of patients with cirrhosis: a prospective multicenter cohort study	11
Inhibition of the U12-type splicing factor ZCRB1 mediates retention of the USP21 minor intron to suppress malignant progression in hepatocellular carcinoma	11
Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC	11